Φορτώνει......
Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials
A primary goal of a phase II dose-ranging trial is to identify a correct dose before moving forward to a phase III confirmatory trial. A correct dose is one that is actually better than control. A popular model in phase II is an independent model that puts no structure on the dose-response relations...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Stat Med |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6606375/ https://ncbi.nlm.nih.gov/pubmed/31070807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/sim.8167 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|